Swissmedic resumes Inspections
Recommendation
10/11 February 2026
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
Swissmedic, the Swiss Agency for Therapeutic Products, has announced "to resume regular on-site inspections", provided that the "necessary protective measures can be complied with". A safe inspection procedure must be guaranteed for all those involved.
Before the GMP/GDP inspection, the company to be inspected must fill out a questionnaire. This questionnaire contains instructions and measures which should be observed during the inspection. The companies are asked to complete the questionnaire and to confirm the measures accordingly.
On site, the inspected company must then make appropriate arrangements, such as "meeting rooms with sufficient space, restricted number of participants, electronic resources" and wearing face masks if necessary.
Related GMP News
03.12.2025What are GMP Audits and what Qualifications do GMP Auditors need to have?
19.11.2025Root Cause Analysis and CAPA - Why FDA Keeps Calling Them Out
22.10.2025EMA Questions & Answers on Mutual Recognition Agreement (MRA) with US updated
22.10.2025FDA continues to take Root Cause Analysis and CAPA very seriously